SUPPLEMENTARY MATERIALS

Supplementary Table 1: Treatment characteristics for all patients who underwent EBRT

| | All courses (N=34) | First course (N=21) | Second course (N=9) | Third course (N=3) | Fourth course (N=1) |
|----------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| EBRT intent | | | | | |
| Curative | 11 (32.4%) | 7 (33.3%) | 3 (33.3%) | 1 (33.3%) | 0 (0.0%) |
| Palliative | 23 (67.6%) | 14 (66.7%) | 6 (66.7%) | 2 (66.7%) | 1 (100.0%) |
| EBRT type | | | | | |
| 2D | 10 (29.4%) | 5 (23.8%) | 4 (44.4%) | 1 (33.3%) | 0 (0.0%) |
| 3D conformal | 3 (8.8%) | 3 (14.3%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| IMRT/VMAT | 17 (50.0%) | 11 (52.4%) | 5 (55.6%) | 1 (33.3%) | 0 (0.0%) |
| SBRT | 1 (2.9%) | 0 (0.0%) | 0 (0.0%) | 1 (33.3%) | 0 (0.0%) |
| SRS | 1 (2.9%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (100.0%) |
| Unknown | 2 (5.9%) | 2 (9.5%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Site(s) of treatment | | | | | |
| Thyroid/Thyroid bed | 26 (76.5%) | 18 (85.7%) | 6 (66.7%) | 2 (66.7%) | 0 (0.0%) |
| Left neck | 21 (61.8%) | 16 (76.2%) | 4 (44.4%) | 1 (33.3%) | 0 (0.0%) |
| Right neck | 22 (64.7%) | 16 (76.2%) | 5 (55.6%) | 1 (33.3%) | 0 (0.0%) |
| Mediastinum | 6 (17.6%) | 3 (14.3%) | 3 (33.3%) | 0 (0.0%) | 0 (0.0%) |
| Metastases | 7 (20.6%) | 2 (9.5%) | 3 (33.3%) | 1 (33.3%) | 1 (100.0%) |
| Other | 2 (5.9%) | 1 (4.8%) | 1 (11.1%) | 0 (0.0%) | 0 (0.0%) |
| Number of fractions | | | | | |
| Median (IQR) | 14.0 (10.0 - 23.0) | 17.0 (11.0 - 27.0) | 10.0 (10.0 - 17.0) | 11.0 (3.0 - 18.0) | 1.0 (1.0 - 1.0) |
| Total dose (cGy) | | | | | |
| Median (IQR) | 3000.0 (2100.0 - 3880.0) | 3500.0 (2500.0 - 4500.0) | 2690.0 (1750.0 - 3000.0) | 2000.0 (1800.0 - 3600.0) | 5900.0 (5900.0 - 5900.0) |
| RT course completion | | | | | |
| Completed | 27 (79.4%) | 15 (71.4%) | 8 (88.9%) | 3 (100.0%) | 1 (100.0%) |

| | All courses (N=34) | First course (N=21) | Second course (N=9) | Third course (N=3) | Fourth course (N=1) |
|--|-----------------------|------------------------|------------------------|-----------------------|------------------------|
| Discontinued early due to toxicity | 3 (8.8%) | 3 (14.3%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Discontinued early due to other reason | 2 (5.9%) | 2 (9.5%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| In-field recurrence | | | | | |
| No | 23 (67.6%) | 14 (66.7%) | 5 (55.6%) | 3 (100.0%) | 1 (100.0%) |
| Yes | 8 (23.5%) | 6 (28.6%) | 2 (22.2%) | 0 (0.0%) | 0 (0.0%) |
| Unknown | 2 (5.9%) | 0 (0.0%) | 2 (22.2%) | 0 (0.0%) | 0 (0.0%) |

Supplementary Table 2. Treatment characteristics for patients who underwent EBRT to the thyroid/thyroid bed/neck


| | All courses (N=29) | First course (N=19) | Second course (N=8) | Third course (N=2) |
|----------------------|-----------------------|------------------------|------------------------|-----------------------|
| EBRT intent | | | | |
| Curative | 10 (34.5%) | 7 (36.8%) | 3 (37.5%) | 0 (0.0%) |
| Palliative | 19 (65.5%) | 12 (63.2%) | 5 (62.5%) | 2 (100.0%) |
| EBRT type | | | | |
| 2D | 9 (31.0%) | 5 (26.3%) | 3 (37.5%) | 1 (50.0%) |
| 3D conformal | 3 (10.3%) | 3 (15.8%) | 0 (0.0%) | 0 (0.0%) |
| IMRT/VMAT | 15 (51.7%) | 9 (47.4%) | 5 (62.5%) | 1 (50.0%) |
| Unknown | 2 (6.9%) | 2 (10.5%) | 0 (0.0%) | 0 (0.0%) |
| Site(s) of treatment | | | | |
| Thyroid/Thyroid bed | 26 (89.7%) | 18 (94.7%) | 6 (75.0%) | 2 (100.0%) |
| Left neck | 21 (72.4%) | 16 (84.2%) | 4 (50.0%) | 1 (50.0%) |
| Right neck | 22 (75.9%) | 16 (84.2%) | 5 (62.5%) | 1 (50.0%) |
| Number of fractions | | | | |
| Median (IQR) | 16.0 (10.0 - 24.0) | 19.0 (12.0 - 30.0) | 10.0 (10.0 - 20.0) | 14.5 (11.0 - 18.0) |

| | All courses (N=29) | First course (N=19) | Second course (N=8) | Third course (N=2) |
|--|-------------------------------------|--------------------------------------|-----------------------------------|------------------------------------|
| Total dose (cGy) | | | | |
| Median (IQR) | 3000.0 (2100.0 - 3880.0) | 3550.0 (2450.0 - 4500.0) | 2380.0 (1500.0 - 3000.0) | 2800.0 (2000.0 - 3600.0) |
| RT course completion | | | | |
| Completed Discontinued early due to toxicity Discontinued early due to | 22 (75.9%) 3 (10.3%) 2 (6.9%) | 13 (68.4%) 3 (15.8%) 2 (10.5%) | 7 (87.5%) 0 (0.0%) 0 (0.0%) | 2 (100.0%) 0 (0.0%) 0 (0.0%) |
| other reason | | | | |
| In-field recurrence No | 20 (69.0%) | 13 (68.4%) | 5 (62 50/) | 2 (100 0%) |
| Yes | 7 (24.1%) | 5 (26.3%) | 5 (62.5%) 2 (25.0%) | 2 (100.0%) 0 (0.0%) |
| Unknown | 1 (3.4%) | 0 (0.0%) | 1 (12.5%) | 0 (0.0%) |

Counts and column percentages are presented unless otherwise specified.


EBRT = External beam radiation therapy; IMRT = Intensity modulated radiation therapy; VMAT = Volumetric modulated arc therapy; RT = Radiotherapy.

Supplementary Figure 1: Recurrence-free survival for patients who underwent EBRT versus no EBRT



| | Total | Events | Censored | 1-Year Survival Rate (95% CI) | Median Survival (months) (95% CI) |
|---------|-------|----------|----------|----------------------------------|--------------------------------------|
| EBRT | 21 | 19 (90%) | 2 (10%) | 0.095 (0.016 - 0.261) | 3.0 (1.0 - 5.0) |
| No EBRT | 7 | 7 (100%) | 0 (0%) | | 1.0 (0.0 - 2.0) |
| Total | 28 | 26 (93%) | 2 (7%) | | |

Supplementary Figure 2: Overall survival for all patients according to treatment regimen



| | Total | Deaths | Censored | 1-Year Survival Rate (95% CI) | Median Survival (months) (95% CI) |
|-------------------------------|-------|----------|----------|----------------------------------|--------------------------------------|
| Surgery + EBRT + Chemotherapy | 10 | 9 (90%) | 1 (10%) | 0.300 (0.071 - 0.578) | 6.5 (3.0 - 14.0) |
| Surgery + EBRT | 5 | 4 (80%) | 1 (20%) | 0.400 (0.052 - 0.753) | 6.0 (4.0 - NE) |
| EBRT + Chemotherapy | 3 | 3 (100%) | 0 (0%) | | 4.0 (0.0 - 11.0) |
| EBRT only | 3 | 3 (100%) | 0 (0%) | | 1.0 (NE - NE) |
| Surgery only | 5 | 5 (100%) | 0 (0%) | | 1.0 (0.0 - 2.0) |
| Chemotherapy only | 1 | 1 (100%) | 0 (0%) | | 1.0 (NE - NE) |
| No treatment | 1 | 1 (100%) | 0 (0%) | | 1.0 (NE - NE) |
| Total | 28 | 26 (93%) | 2 (7%) | | |

NE = Non-evaluable